Biogen touts ‘resilience’ but gives little guidance on Alzheimer’s drug

Biogen’s CEO Michel Vounatsos painted the drugmaker as a resilient fighter during a year-end investor call Thursday, while laying out the strategy for several major crusades that lie ahead.